Environmental Challenges of Pharmaceuticals: Persistence and Accumulation in Ecosystems

Importance of the Topic

Pharmaceuticals have become persistent micropollutants due to extensive use in human and veterinary medicine and livestock feed. They enter water bodies through wastewater, effluents, and sludge, accumulating at ng/L to µg/L levels. Their resistance to degradation and potential to foster antimicrobial resistance make them a critical environmental and public health concern.

Objectives and Study Overview

The document from EnviroMail No. 21 examines the environmental fate of pharmaceuticals across ecosystems, assesses removal efficiencies in conventional wastewater treatment plants (WWTPs), and reviews evolving European legislation. It also presents ALS laboratory research on removal rates of common and regulated compounds.

Methodology and Instrumentation

The study employed mechanical-biological treatment simulations typical of municipal WWTPs to evaluate removal efficiencies. ALS laboratories developed multiresidue methods for over 100 pharmaceuticals and metabolites in water samples. All analyses utilized liquid chromatography coupled with tandem mass spectrometry (LC/MS/MS) for high sensitivity, selectivity, and precision at trace concentration levels.

Key Results and Discussion

• Removal efficiencies for the most frequently detected pharmaceuticals reached 80–90% in standard WWTP processes.
• Compounds proposed for future EU monitoring showed average removal rates near 20%, underscoring monitoring needs.
• Pharmaceutical entry pathways include treated wastewater discharges, sewage sludge used as fertilizer, livestock excretion, and industrial effluents.
• Table of regulated substances covers 12 parameters including antibiotics (e.g., azithromycin, clarithromycin), antidepressants (citalopram), antiepileptics (carbamazepine), beta-blockers, diuretics, NSAIDs, hormones, psycholeptics, and RAS agents.
• EU directives aim for an 80% removal target by 2045 for WWTPs serving populations over 150,000, with mandatory monitoring of antimicrobial resistance in large agglomerations.

Benefits and Practical Applications

• Enhanced analytical methods enable trace-level detection and compliance verification with upcoming regulations.
• Data support WWTP process optimization to reduce pharmaceutical loads in surface and drinking water.
• Insights into removal limitations guide investment in advanced treatment technologies.
• Comprehensive monitoring frameworks aid risk assessment and management of antimicrobial resistance.

Future Trends and Opportunities

• Integration of advanced oxidation processes, membrane filtration, and hybrid treatment systems for improved removal.
• Expansion of monitoring lists to include emerging pharmaceutical classes and transformation products.
• Use of high-resolution mass spectrometry and data analytics for non-target screening and predictive modeling.
• Development of regulatory frameworks addressing combined effects and antibiotic resistance proliferation.

Conclusion

Pharmaceuticals pose complex environmental challenges due to persistence and low-concentration toxicity. Conventional WWTPs achieve variable removal rates, highlighting the need for regulatory enforcement of stringent removal targets and advanced analytical and treatment solutions. Ongoing research and policy evolution will be essential to mitigate ecological impacts and safeguard public health.

References

1. DOI: 10.1016/j.jhazmat.2009.10.100
2. European Parliament legislative resolution: Document P9_TA(2024)0222
3. Proposal for a Directive of the European Parliament: Document 52022PC0540
4. Commission Implementing Decision (EU) 2022/679: Document 32022D0679